ArticleJournal of the American College of Cardiology2023
Impact of Transcatheter Mitral Valve Repair Availability on Volume and Outcomes of Surgical Repair.
Article in Journal of the American College of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 18 citations in OpenAlex.
- Trainee exposure to valve surgery in the UK: safety, decline and organisational inequality in a national cohort.Open heart · 2026Article
- Temporal Trends in Mitral Valve Repair Procedures and Outcomes Among Older U.S. Adults.JACC. Advances · 2026Article
- National Trends in Mitral Valve Surgery Outcomes in Centers With and Without Mitral Transcatheter Edge-to-Edge Repair.Annals of thoracic surgery short reports · 2025Article
- A nationwide analysis of resource utilization and safety in patients undergoing mitral transcatheter edge-to-edge repair.International journal of cardiology. Heart & vasculature · 2025Article
- The multidisciplinary heart team: gatekeeper or last resort?Proceedings (Baylor University. Medical Center)Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundThe impact of transcatheter edge-to-edge repair (TEER) on national surgical mitral valve repair (MVr) volume and outcomes is unknown.
objectivesThis study aims to assess the impact of TEER availability on MVr volumes and outcomes for degenerative mitral regurgitation.
methodsMVr volume, 30-day and 5-year outcomes, including mortality, heart failure rehospitalization and mitral valve reintervention, were obtained from the Society of Thoracic Surgeons database linked with Medicare administrative claims and were compared within TEER centers before and after the first institutional TEER procedure. A difference-in-difference approach comparing parallel trends in coronary artery bypass grafting outcomes was used to account for temporal improvements in perioperative care.
resultsFrom July 2011 through December 2018, 13,959 patients underwent MVr at 278 institutions, which became TEER-capable during the study period. There was no significant change in median annualized institutional MVr volume before (32 [IQR: 17-54]) vs after (29 [IQR: 16-54]) the first TEER (P = 0.06). However, higher-risk (Society of Thoracic Surgeons predicted risk of mortality ≥2%) MVr procedures declined over the study period (P < 0.001 for trend). The introduction of TEER was associated with reduced risk-adjusted odds of mortality after MVr at 30 days (adjusted OR: 0.73; 95% CI: 0.54-0.99) and over 5 years (adjusted HR: 0.75; 95% CI: 0.66-0.86). These improvements in 30-day and 5-year mortality were significantly greater than equivalent trends in coronary artery bypass grafting.
conclusionsThe introduction of TEER has not significantly changed overall MVr case volumes for degenerative mitral regurgitation but is associated with a decrease in higher-risk surgical operations and improved 30-day and 5-year outcomes within institutions adopting the technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.